Evidence map›Paper›PMID 41419692›Full record

ArticleInternational journal of clinical oncology2026

Radiotherapy with or without chemotherapy for T2N0 hypopharyngeal cancer: an analysis of the head and neck cancer registry of Japan.

Ari Nishimura, Naoki Fukuda, Daisuke Kawakita, Megumi Kitayama, Ken-Ichi Nibu, Seiichi Yoshimoto, Hirokazu Uemura, Tadashi Kitahara

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ari Nishimura *Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan. a.nishimura@naramed-u.ac.jp.ORCID http://orcid.org/0000-0001-5176-2433
Naoki Fukuda *Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Daisuke KawakitaJapanese Society for Head and Neck Cancer, Tokyo, Japan.
Megumi KitayamaJapanese Society for Head and Neck Cancer, Tokyo, Japan.
Ken-Ichi NibuJapanese Society for Head and Neck Cancer, Tokyo, Japan.
Seiichi YoshimotoJapanese Society for Head and Neck Cancer, Tokyo, Japan.
Hirokazu UemuraDepartment of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan.
Tadashi KitaharaDepartment of Otolaryngology-Head and Neck Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis retrospective study compared the outcomes of radiotherapy (RT) and chemoradiotherapy (CRT) in patients with T2N0 hypopharyngeal cancer.

methodsWe analyzed patients with T2N0 hypopharyngeal squamous cell carcinoma treated with RT or CRT between 2011 and 2016 using data from the Head and Neck Cancer Registry of Japan.

resultsAmong 53,512 patients, 457 with T2N0 disease received RT (n = 165) or CRT (n = 292; median follow-up, 41.8 months; median age, 70 years). Tumor sites included the pyriform sinus (72.9%), postcricoid region (12.3%), posterior wall (11.8%), and unknown (3.1%). The groups differed in terms of age and alcohol use. Before weighing, CRT was associated with longer PFS and a lower cumulative incidence of locoregional recurrence compared with RT. However, in the IPTW-adjusted analysis, CRT did not significantly improve OS (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.59-1.62) or PFS (HR, 0.79; 95% CI, 0.53-1.16) compared with RT. PFS was associated with alcohol/smoking history, performance status, and primary site of the tumor.

conclusionIn T2N0 hypopharyngeal cancer, CRT reduced the locoregional recurrence compared to RT. However, CRT did not confer a significant OS or PFS advantage over RT after adjustment for baseline imbalances. RT alone may, therefore, be a reasonable definitive treatment option for selected patients.

Indexed as

ChemoradiotherapyHead and Neck NeoplasmsHypopharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingRegistriesRetrospective StudiesChemoradiotherapyHypopharyngeal cancerProgression-free survivalRadiotherapyT2N0

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.